Published in Osteoporos Int on September 19, 2003
A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int (2007) 3.50
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int (2006) 2.53
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int (2006) 1.56
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract (2006) 1.46
The role of zoledronic acid in the management of osteoporosis. Clin Rheumatol (2010) 1.44
Long-term effect of the Women's Health Initiative study on antiosteoporosis medication prescribing. J Womens Health (Larchmt) (2010) 1.41
Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int (2007) 1.33
Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med (2008) 1.25
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int (2008) 1.24
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Adherence to treatment of osteoporosis: a need for study. Osteoporos Int (2007) 1.13
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab (2007) 1.11
Patients' adherence to osteoporosis therapy: exploring the perceptions of postmenopausal women. Can Fam Physician (2008) 1.08
Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int (2010) 1.07
Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int (2008) 1.03
Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int (2008) 1.02
Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int (2008) 1.01
Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int (2010) 1.00
The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord (2007) 0.99
A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int (2011) 0.98
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int (2010) 0.97
Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int (2008) 0.95
The role of counselling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci (2013) 0.94
Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol (2009) 0.93
Adherence to alendronate in male veterans. Osteoporos Int (2007) 0.92
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf (2010) 0.88
Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture. Ther Adv Musculoskelet Dis (2009) 0.88
Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med (2011) 0.87
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisphosphonates: the BP-MUSASHI study. Osteoporos Int (2014) 0.85
Adherence to osteoporosis medications amongst Singaporean patients. Osteoporos Int (2011) 0.84
Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med (2010) 0.84
Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int (2005) 0.83
A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int (2011) 0.83
Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord (2013) 0.83
Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet Disord (2011) 0.83
Persistence of weekly alendronate: a real-world study in Croatia. Clin Rheumatol (2008) 0.83
Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos (2015) 0.82
Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging (2009) 0.82
Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis (2010) 0.82
Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol (2008) 0.82
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int (2005) 0.82
Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women. J Bone Miner Metab (2009) 0.81
Clinical experience with intravenous zoledronic acid in the treatment of male osteoporosis: evidence and opinions. Ther Adv Musculoskelet Dis (2013) 0.81
The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporos Int (2005) 0.81
Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. Clinicoecon Outcomes Res (2013) 0.80
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc (2010) 0.79
Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. J Bone Miner Metab (2013) 0.79
Adherence to raloxifene therapy: assessment methods and relationship with efficacy. Osteoporos Int (2013) 0.78
Zoledronic Acid for the treatment and prevention of primary and secondary osteoporosis. Ther Adv Musculoskelet Dis (2010) 0.78
Denosumab in postmenopausal osteoporosis: what the clinician needs to know. Ther Adv Musculoskelet Dis (2009) 0.78
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clin Interv Aging (2008) 0.78
Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics (2008) 0.78
Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: an empirical approach based on healthcare utilisation databases. BMJ Open (2014) 0.78
Bone health-related factors and the use of bisphosphonates in community setting--15-year follow-up study. Osteoporos Int (2010) 0.77
Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database. Clin Cases Miner Bone Metab (2016) 0.76
Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures. Osteoporos Int (2010) 0.76
Adherence with bisphosphonate therapy and change in bone mineral density among women with osteoporosis or osteopenia in clinical practice. Osteoporos Int (2012) 0.76
Once-monthly risedronate for postmenopausal osteoporosis. Int J Womens Health (2010) 0.76
A qualitative study of community pharmacists' opinions on the provision of osteoporosis disease state management services in Malaysia. BMC Health Serv Res (2016) 0.75
Implementing adherence to osteoporosis treatments. Clin Cases Miner Bone Metab (2009) 0.75
Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest (2017) 0.75
Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients. J Bone Miner Metab (2014) 0.75
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet (1996) 13.20
Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med (1995) 3.29
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med (2000) 3.16
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med (2002) 2.27
Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause (1999) 0.93
Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol (2000) 0.87
Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause (2001) 0.84
Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy. Am J Manag Care (1999) 0.83
How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med (2000) 0.79
The digital divide in adoption and use of a personal health record. Arch Intern Med (2011) 3.69
Validation of a surveillance case definition for arthritis. J Rheumatol (2005) 1.85
Optimizing practice through research: a new perspective to solve an old problem. Ann Fam Med (2008) 1.60
A comparison of health-care costs in patients with chronic obstructive pulmonary disease using lightweight portable oxygen systems versus traditional compressed-oxygen systems. Respir Care (2008) 1.51
Challenges of estimating health service utilization for osteoarthritis patients on a population level. J Rheumatol (2002) 1.48
A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation. J Manag Care Pharm (2013) 1.43
"Under the radar": nurse practitioner prescribers and pharmaceutical industry promotions. Am J Manag Care (2010) 1.40
The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol (2002) 1.26
Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med (2008) 1.25
Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med (2005) 1.03
The Lower Extremity Gain Scale: a performance-based measure to assess recovery after hip fracture. Arch Phys Med Rehabil (2006) 1.02
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Impact of case ascertainment on recent trends in diabetes incidence in Rochester, Minnesota. Am J Epidemiol (2002) 0.99
The direct medical costs of undiagnosed chronic obstructive pulmonary disease. Value Health (2008) 0.99
A mobile app for securely capturing and transferring clinical images to the electronic health record: description and preliminary usability study. JMIR Mhealth Uhealth (2015) 0.98
Adherence to inhaled corticosteroid use and local adverse events in persistent asthma. Am J Manag Care (2008) 0.97
A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics (2010) 0.93
Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan. Am J Health Syst Pharm (2007) 0.91
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol (2006) 0.91
Cutaneous immunoglobulin G4-related systemic disease. Am J Med (2011) 0.87
Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD (2007) 0.84
A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization. Cutis (2006) 0.80
Impact of bipolar disorder on the family: utilization and cost of health care resources. P T (2008) 0.75
Identifying unrecognized peripheral arterial disease among asymptomatic patients in the primary care setting. Angiology (2006) 0.75
Compliance with oral HRT in postmenopausal women in clinical trials--meta analysis. Maturitas (2003) 0.75
Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan. Drugs Aging (2011) 0.75